The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive ...

High-yield dividend stocks may not appeal to some investors. However, if you're among those investors looking for income, ...

New York, USA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Myocardial Infarction Clinical Trial Pipeline Appears Robust With 45+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight ...

An investigational induced pluripotent stem cell-derived CAR natural killer cell therapy was well tolerated both as ...

Organon has faced significant price volatility and underperformance since its spin-off from Merck. Check out why I recommend ...

It's not the first therapy in the oncolytic virus class to be approved around the world, as that accolade went to Amgen's Imlygic ... and is also its fourth cancer product approval in the last ...

The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients ...

Amgen and Metsera are the two companies that seem to be pioneering the option of once-monthly dosing obesity medicine, according to the report. However, for these ultra-long-acting candidates to ...

Blue Origin 'thrilled' with inaugural New Glenn launch despite fail at recovering booster A Philadelphia sports fan, who went ...